Tillman Gerngross is betting well over $500M that the pandemic will never really end. Here’s the IPO pitch
Tillman Gerngross doesn’t waffle.
The longtime Dartmouth professor and Adimab founder tends to pick a course and drive straight for the goal. If he sees a big, ugly nail, he’ll start to design a hammer for it. And jumping straight into the global pandemic, he quickly decided that he had the best shot at producing a powerful antibody that could protect billions of people from the worst public health crisis in a century.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
